See more : Mysore Petro Chemicals Limited (MYSORPETRO.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Harvard Bioscience, Inc. (HBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Harvard Bioscience, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
You may be interested
- PARATUS ENERGY SERVICES LTD (PLSV.OL) Income Statement Analysis – Financial Results
- Quanta Services, Inc. (PWR) Income Statement Analysis – Financial Results
- Tailim Packaging Co., Ltd. (011280.KS) Income Statement Analysis – Financial Results
- The Williams Companies, Inc. (WMB.DE) Income Statement Analysis – Financial Results
- Plazza AG (0R8X.L) Income Statement Analysis – Financial Results
Harvard Bioscience, Inc. (HBIO)
Industry: Medical - Instruments & Supplies
Sector: Healthcare
Website: https://www.harvardbioscience.com
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 112.25M | 113.34M | 118.90M | 102.10M | 116.18M | 120.77M | 101.88M | 104.52M | 108.66M | 108.66M | 105.17M | 111.17M | 108.86M | 108.18M | 85.77M | 88.05M | 83.41M | 76.18M | 67.43M | 92.60M | 87.14M | 57.38M | 40.87M | 30.57M | 26.18M | 12.15M |
| Cost of Revenue | 46.18M | 52.52M | 51.25M | 44.06M | 51.85M | 57.59M | 54.29M | 56.11M | 59.94M | 59.32M | 57.48M | 58.75M | 58.60M | 56.40M | 44.09M | 45.89M | 43.16M | 38.09M | 34.16M | 46.52M | 43.73M | 28.82M | 20.64M | 15.10M | 12.72M | 5.35M |
| Gross Profit | 66.07M | 60.82M | 67.65M | 58.04M | 64.32M | 63.18M | 47.60M | 48.42M | 48.72M | 49.34M | 47.70M | 52.42M | 50.26M | 51.78M | 41.68M | 42.16M | 40.25M | 38.09M | 33.28M | 46.07M | 43.41M | 28.56M | 20.23M | 15.47M | 13.46M | 6.80M |
| Gross Profit Ratio | 58.86% | 53.66% | 56.90% | 56.85% | 55.37% | 52.31% | 46.72% | 46.32% | 44.84% | 45.41% | 45.35% | 47.15% | 46.17% | 47.86% | 48.60% | 47.88% | 48.25% | 50.00% | 49.35% | 49.76% | 49.82% | 49.77% | 49.50% | 50.61% | 51.40% | 55.97% |
| Research & Development | 11.76M | 12.33M | 10.80M | 8.69M | 10.72M | 10.99M | 5.65M | 5.39M | 6.42M | 4.88M | 4.15M | 7.32M | 5.43M | 4.71M | 4.40M | 4.05M | 3.71M | 3.15M | 2.95M | 7.19M | 6.26M | 4.15M | 3.18M | 1.53M | 1.19M | 325.00K |
| General & Administrative | 22.78M | 24.49M | 24.31M | 23.51M | 22.76M | 21.38M | 18.58M | 20.95M | 19.83M | 16.83M | 19.94M | 19.70M | 18.06M | 17.64M | 15.11M | 26.10M | 25.18M | 24.55M | 20.74M | 31.06M | 26.78M | 18.89M | 14.52M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 24.11M | 25.04M | 24.64M | 19.92M | 23.26M | 24.44M | 21.04M | 20.49M | 20.58M | 18.23M | 17.33M | 19.17M | 17.47M | 16.35M | 11.76M | 10.97M | 10.35M | 9.50M | 8.11M | 16.82M | 15.38B | 8.44B | 4.84B | 0.00 | 0.00 | 0.00 |
| SG&A | 46.89M | 49.53M | 48.95M | 43.43M | 46.02M | 45.83M | 39.61M | 41.44M | 40.41M | 35.05M | 37.27M | 38.87M | 35.54M | 33.99M | 26.87M | 26.10M | 25.18M | 24.55M | 20.74M | 31.06M | 26.78M | 18.89M | 14.52M | 22.78M | 9.88M | 4.04M |
| Other Expenses | 5.60M | 6.12M | 5.84M | 5.71M | 5.75M | -4.28M | -740.00K | -179.00K | -1.26M | -1.14M | -51.00K | -287.00K | 2.75M | 2.36M | 1.84M | 1.97M | 1.82M | 1.70M | 1.67M | 3.45M | 2.70M | 1.54M | 1.74M | 1.49M | 1.26M | 27.00K |
| Operating Expenses | 64.50M | 67.99M | 65.59M | 57.82M | 62.49M | 62.20M | 47.70M | 49.55M | 49.65M | 42.51M | 44.01M | 48.94M | 43.72M | 41.06M | 33.11M | 32.12M | 30.71M | 29.40M | 25.35M | 41.69M | 35.75M | 24.58M | 19.44M | 25.80M | 12.32M | 4.39M |
| Cost & Expenses | 110.36M | 120.50M | 116.84M | 101.88M | 114.34M | 119.79M | 101.98M | 105.66M | 109.59M | 101.83M | 101.48M | 107.70M | 102.32M | 97.46M | 77.20M | 78.01M | 73.87M | 67.49M | 59.51M | 88.22M | 79.48M | 53.40M | 40.08M | 40.90M | 25.04M | 9.74M |
| Interest Income | 0.00 | 2.55M | 1.54M | 4.83M | 5.41M | 0.00 | 0.00 | 3.00K | 8.00K | 74.00K | 43.00K | 46.00K | 65.00K | 65.00K | 29.00K | 372.00K | 317.00K | 216.00K | 234.00K | 136.00K | 175.99K | 445.67K | 1.36M | 159.85K | 0.00 | 0.00 |
| Interest Expense | 3.59M | 2.25M | 1.54M | 4.83M | 5.41M | 5.37M | 713.00K | 642.00K | 854.00K | 990.00K | 955.00K | 584.00K | 752.00K | 677.00K | 277.00K | 389.00K | 365.00K | 429.00K | 917.00K | 794.00K | 327.23K | 104.18K | 6.87K | 916.21K | 0.00 | 0.00 |
| Depreciation & Amortization | 7.00M | 7.58M | 7.62M | 7.63M | 7.73M | 7.84M | 2.91M | 4.27M | 2.82M | 2.58M | 3.99M | 4.21M | 2.75M | 2.36M | 1.84M | 3.10M | 3.47M | 3.34M | 5.04M | 6.35M | 5.29M | 3.01M | 2.97M | 1.49M | 1.26M | 27.00K |
| EBITDA | 8.03M | 944.00K | 11.31M | 5.49M | 7.50M | 5.36M | -101.00K | 1.80M | 1.73M | 9.29M | 7.67M | 11.68M | 11.95M | 13.80M | 13.14M | 11.14M | 9.53M | 8.69M | 12.96M | 14.73M | 12.95M | 6.99M | 3.76M | -8.84M | 2.39M | 2.44M |
| EBITDA Ratio | 7.16% | -0.92% | 6.09% | 5.02% | 6.21% | 1.73% | 1.57% | 1.35% | 0.59% | 7.69% | 7.29% | 6.69% | 8.59% | 12.15% | 12.18% | 17.61% | 15.50% | 15.89% | 19.37% | 11.39% | 15.17% | 15.61% | 22.79% | 93.51% | 122.81% | 20.07% |
| Operating Income | 1.89M | -7.17M | 1.40M | -585.00K | 1.47M | 984.00K | -101.00K | -3.00M | -1.71M | 6.62M | 1.54M | 3.17M | 6.08M | 10.22M | 8.06M | 8.48M | 9.53M | 8.69M | 7.92M | 4.38M | 7.67M | 1.64M | -4.66M | -10.33M | 1.13M | 2.41M |
| Operating Income Ratio | 1.69% | -6.32% | 1.18% | -0.57% | 1.27% | 0.81% | -0.10% | -2.87% | -1.58% | 6.09% | 1.46% | 2.85% | 5.58% | 9.45% | 9.39% | 9.63% | 11.43% | 11.41% | 11.75% | 4.73% | 8.80% | 2.86% | -11.40% | -33.77% | 4.33% | 19.85% |
| Total Other Income/Expenses | -4.45M | -2.25M | -2.21M | -7.51M | -5.88M | -8.96M | -1.99M | -81.00K | -1.90M | -2.20M | -1.10M | -5.60M | -1.54M | -655.00K | 1.76M | -829.00K | 35.00K | -294.00K | -784.00K | 3.25M | -428.00K | 707.00K | 1.24M | -38.18M | -30.42M | -1.56M |
| Income Before Tax | -2.56M | -9.18M | -140.00K | -7.29M | -5.50M | -8.52M | -2.09M | -3.08M | -3.61M | 4.42M | 435.00K | 2.23M | 4.54M | 9.56M | 9.81M | 7.65M | 9.57M | 8.40M | 7.14M | 3.80M | 7.24M | 2.35M | -3.42M | -48.51M | -29.28M | 854.00K |
| Income Before Tax Ratio | -2.28% | -8.10% | -0.12% | -7.14% | -4.74% | -7.05% | -2.05% | -2.94% | -3.32% | 4.06% | 0.41% | 2.00% | 4.17% | 8.84% | 11.44% | 8.69% | 11.47% | 11.02% | 10.59% | 4.10% | 8.30% | 4.09% | -8.36% | -158.66% | -111.86% | 7.03% |
| Income Tax Expense | 859.00K | 337.00K | 148.00K | 518.00K | -815.00K | -3.68M | -1.22M | 1.23M | 15.43M | 2.06M | -288.00K | 696.00K | 730.00K | -9.45M | 2.67M | 2.24M | 1.97M | 1.78M | 899.00K | 1.47M | 2.98M | 1.61M | 1.79M | 1.36M | 137.48K | 783.00K |
| Net Income | -3.42M | -9.52M | -288.00K | -7.81M | -4.69M | -3.46M | -865.00K | -4.31M | -19.04M | 2.36M | -1.83M | 2.37M | 3.81M | 19.02M | 7.23M | 1.67M | -1.35M | -2.34M | -31.88M | 2.33M | 4.26M | 737.33K | -5.21M | -49.87M | -29.42M | 71.00K |
| Net Income Ratio | -3.04% | -8.40% | -0.24% | -7.65% | -4.03% | -2.87% | -0.85% | -4.12% | -17.52% | 2.17% | -1.74% | 2.13% | 3.50% | 17.58% | 8.43% | 1.90% | -1.62% | -3.07% | -47.27% | 2.52% | 4.89% | 1.28% | -12.74% | -163.11% | -112.38% | 0.58% |
| EPS | -0.08 | -0.23 | -0.01 | -0.20 | -0.12 | -0.10 | -0.03 | -0.13 | -0.57 | 0.07 | -0.06 | 0.09 | 0.13 | 0.66 | 0.24 | 0.05 | -0.04 | -0.08 | -1.05 | 0.08 | 0.14 | 0.03 | -0.20 | -6.23 | -5.25 | -0.01 |
| EPS Diluted | -0.08 | -0.23 | -0.01 | -0.20 | -0.12 | -0.10 | -0.02 | -0.13 | -0.57 | 0.07 | -0.06 | 0.08 | 0.13 | 0.65 | 0.24 | 0.05 | -0.04 | -0.08 | -1.04 | 0.07 | 0.14 | 0.03 | -0.20 | -6.23 | -5.25 | -0.01 |
| Weighted Avg Shares Out | 42.42M | 41.41M | 40.34M | 38.64M | 37.81M | 35.83M | 33.60M | 34.21M | 33.59M | 32.17M | 30.38M | 28.80M | 28.45M | 28.97M | 29.65M | 30.88M | 30.65M | 30.52M | 30.44M | 30.27M | 29.92M | 27.09M | 25.78M | 8.01M | 5.60M | 5.60M |
| Weighted Avg Shares Out (Dil) | 42.42M | 41.41M | 40.34M | 38.64M | 37.81M | 36.45M | 34.75M | 34.21M | 33.59M | 33.24M | 31.91M | 29.79M | 29.82M | 29.41M | 29.95M | 31.35M | 31.41M | 31.15M | 30.78M | 31.10M | 30.71M | 27.60M | 25.78M | 8.01M | 5.60M | 5.60M |
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
HOLLISTON, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2023.
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting
Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analytics Solutions for CROs, pharma and biotechs improve throughput and efficiency and enable future advancements in data analytics
Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET
HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to...
Harvard Bioscience to Present at Benchmark Company's Discovery One-On-One Investor Conference on December 7, 2023
HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12th Annual Discovery One-on-One Investor Conference to be held Thursday December 7th, 2023 at the New York...
Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023
HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwest IDEAS Investor Conference on Thursday November 16, 2023 at The...
Harvard Bioscience, Inc. (HBIO) Q3 2023 Earnings Call Transcript
Harvard Bioscience, Inc. (NASDAQ:HBIO ) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Dave Sirois - Director, Corporate Accounting & SEC Reporting James Green - Chairman, President & Chief Executive Officer Jennifer Cote - Chief...
Harvard Bioscience Announces Third Quarter 2023 Financial Results
HOLLISTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2023.
Harvard Bioscience to Showcase Latest Innovations in Preclinical and Organoid Research at Society for Neuroscience Conference on November 12-15, 2023
HOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C.
Harvard Bioscience Schedules Third Quarter 2023 Earnings Conference Call for November 7, 2023 at 8:00 AM ET
HOLLISTON, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2023 before the market opens on November 7, 2023, and will hold a conference call to...
Harvard Bioscience and Etisense Announce Agreement for Supply and Distribution of DECRO Miniature Telemetry Jacket Platform for Pre-Clinical Research
Includes dedicated version for integration with Ponemah data management software from Data Sciences International (DSI)
Source: https://incomestatements.info
Category: Stock Reports